NASDAQ:OFIX Orthofix Medical (OFIX) Stock Price, News & Analysis → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Free OFIX Stock Alerts $14.90 +1.01 (+7.27%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$14.53▼$15.8750-Day Range$12.99▼$14.9052-Week Range$9.57▼$21.60Volume762,905 shsAverage Volume409,801 shsMarket Capitalization$557.41 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Orthofix Medical alerts: Email Address Orthofix Medical MarketRank™ Stock AnalysisAnalyst RatingHold2.25 Rating ScoreUpside/Downside20.8% Upside$18.00 Price TargetShort InterestBearish10.10% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.51Based on 20 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.51) to ($0.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.99 out of 5 starsMedical Sector638th out of 905 stocksSurgical & Medical Instruments Industry73rd out of 95 stocks 2.1 Analyst's Opinion Consensus RatingOrthofix Medical has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageOrthofix Medical has only been the subject of 2 research reports in the past 90 days.Read more about Orthofix Medical's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.10% of the outstanding shares of Orthofix Medical have been sold short.Short Interest Ratio / Days to CoverOrthofix Medical has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.Change versus previous monthShort interest in Orthofix Medical has recently decreased by 1.56%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldOrthofix Medical does not currently pay a dividend.Dividend GrowthOrthofix Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OFIX. Previous Next 3.1 News and Social Media Coverage News SentimentOrthofix Medical has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Orthofix Medical this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for OFIX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Orthofix Medical to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Orthofix Medical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.70% of the stock of Orthofix Medical is held by insiders.Percentage Held by Institutions89.76% of the stock of Orthofix Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Orthofix Medical's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Orthofix Medical are expected to grow in the coming year, from ($1.51) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Orthofix Medical is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Orthofix Medical is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrthofix Medical has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Orthofix Medical's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlace$21,000 in profits in six weeks? On Wednesday, May 8, the legendary Jonathan Rose is holding his first ever Masters in Trading Summit. Jonathan is one of the sharpest traders I’ve ever met. He made millions trading in the pits of the world’s largest exchanges.Click here for details. About Orthofix Medical Stock (NASDAQ:OFIX)Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations. The Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.Read More OFIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OFIX Stock News HeadlinesMay 8, 2024 | msn.comRoth MKM ups Orthofix to buy, cites improving fundamentalsMay 8, 2024 | finance.yahoo.comOrthofix Medical Inc. (NASDAQ:OFIX) Q1 2024 Earnings Call TranscriptMay 8, 2024 | Behind the Markets (Ad)The Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.May 8, 2024 | finance.yahoo.comOrthofix Medical Inc (OFIX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ...May 7, 2024 | investorplace.comOFIX Stock Earnings: Orthofix Medical Meets EPS, Beats Revenue for Q1 2024May 7, 2024 | markets.businessinsider.comOrthofix Medical Inc. Q1 Loss decreases, but misses estimatesMay 7, 2024 | finance.yahoo.comOrthofix Reports First Quarter 2024 ResultsMay 7, 2024 | finance.yahoo.comOrthofix Medical Inc. (OFIX) Q1 2024 Earnings: Revenue Surpasses Estimates Amidst Net Loss WideningMay 8, 2024 | Behind the Markets (Ad)The Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.May 7, 2024 | seekingalpha.comOrthofix Medical Inc. 2024 Q1 - Results - Earnings Call PresentationMay 7, 2024 | americanbankingnews.comBrokers Issue Forecasts for Orthofix Medical Inc.'s Q1 2025 Earnings (NASDAQ:OFIX)May 5, 2024 | americanbankingnews.comOrthofix Medical (OFIX) to Release Earnings on TuesdayApril 26, 2024 | msn.comMarriott Vacations, Carrols Restaurant Group, and More Stocks See Action From Activist InvestorsApril 23, 2024 | businesswire.comOrthofix Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024April 22, 2024 | finance.yahoo.comSacroiliac Joint Fusion Market To Reach USD 4,106.7 Billion By 2032 | DataHorizzon ResearchApril 22, 2024 | markets.businessinsider.comStryker’s Resilience Amidst Competitive Pressures Reinforces Buy RatingApril 19, 2024 | markets.businessinsider.comOrthofix (OFIX) Gets a Hold from JMP SecuritiesApril 16, 2024 | finance.yahoo.comOrthofix Names Andres Cedron as New Chief Legal OfficerApril 1, 2024 | uk.finance.yahoo.comMesenchymal Stem Cells (MSCs) Advancements & Global Market Potential Highlighted in Comprehensive Strategic ReportMarch 28, 2024 | tmcnet.comBRIJ Medical Bolsters Leadership Team: John Grotting Named Chairman, Bob Zollars and Jim Hinrichs Join BoardMarch 7, 2024 | finance.yahoo.comOrthofix Medical Inc (OFIX) Reports Significant Sales Growth and Improved EBITDA in Q4 and Full ...March 6, 2024 | ca.finance.yahoo.comOrthofix Medical Inc. (OM2.F)March 6, 2024 | msn.comOrthofix GAAP EPS of -$0.59 misses by $0.10, revenue of $200.4M beats by $4.83MMarch 6, 2024 | finance.yahoo.comQ4 2023 Orthofix Medical Inc Earnings CallMarch 5, 2024 | investorplace.comOFIX Stock Earnings: Orthofix Medical Misses EPS, Beats Revenue for Q4 2023March 5, 2024 | seekingalpha.comOrthofix Medical Inc. 2023 Q4 - Results - Earnings Call PresentationMarch 5, 2024 | businesswire.comOrthofix Reports Fourth Quarter and Full Year 2023 ResultsSee More Headlines Receive OFIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orthofix Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today5/08/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:OFIX CUSIPN6748L10 CIK884624 Webwww.orthofix.com Phone(214) 937-2000Fax599 9 461 6978Employees1,634Year Founded1980Price Target and Rating Average Stock Price Target$18.00 High Stock Price Target$20.00 Low Stock Price Target$16.00 Potential Upside/Downside+20.8%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($4.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-151,400,000.00 Net Margins-20.28% Pretax Margin-19.91% Return on Equity-10.63% Return on Assets-7.34% Debt Debt-to-Equity Ratio0.19 Current Ratio2.54 Quick Ratio1.20 Sales & Book Value Annual Sales$746.64 million Price / Sales0.75 Cash FlowN/A Price / Cash FlowN/A Book Value$16.11 per share Price / Book0.92Miscellaneous Outstanding Shares37,410,000Free Float35,649,000Market Cap$557.41 million OptionableOptionable Beta1.06 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMs. Kimberley A. Elting (Age 59)President of Global Orthopedics Comp: $766.67kMs. Julie B. Andrews (Age 53)Chief Financial Officer Mr. Roberto DonadelloSenior Vice President of Global OperationsMr. Dan E. YarbroughVice President of Investor RelationsMs. Jill MasonInterim Chief Ethics & Compliance Officer and VP of Corporate CounselMr. Ehab M. Esmail (Age 52)Senior Vice President of Global Quality, Regulatory & Clinical Affairs Mr. Tyler P. Lipschultz (Age 57)President of Global Biologics Dr. Beau Standish P.Eng. (Age 43)Ph.D., President of Global Enabling Technologies Mr. Geoffrey C. GillespieVP & Corporate ControllerMore ExecutivesKey CompetitorsSurmodicsNASDAQ:SRDXAngioDynamicsNASDAQ:ANGOAccurayNASDAQ:ARAYIntersect ENTNASDAQ:XENTAtriCureNASDAQ:ATRCView All CompetitorsInsiders & InstitutionsRussell Investments Group Ltd.Sold 12,670 shares on 5/8/2024Ownership: 0.592%Swiss National BankSold 7,100 shares on 5/7/2024Ownership: 0.175%Sei Investments Co.Sold 1,760 shares on 5/7/2024Ownership: 0.099%SG Americas Securities LLCSold 6,385 shares on 5/7/2024Ownership: 0.046%GSA Capital Partners LLPBought 63,412 shares on 5/3/2024Ownership: 0.170%View All Insider TransactionsView All Institutional Transactions OFIX Stock Analysis - Frequently Asked Questions Should I buy or sell Orthofix Medical stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Orthofix Medical in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OFIX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OFIX, but not buy additional shares or sell existing shares. View OFIX analyst ratings or view top-rated stocks. What is Orthofix Medical's stock price target for 2024? 4 Wall Street analysts have issued 12-month target prices for Orthofix Medical's shares. Their OFIX share price targets range from $16.00 to $20.00. On average, they predict the company's stock price to reach $18.00 in the next year. This suggests a possible upside of 20.8% from the stock's current price. View analysts price targets for OFIX or view top-rated stocks among Wall Street analysts. How have OFIX shares performed in 2024? Orthofix Medical's stock was trading at $13.48 at the start of the year. Since then, OFIX stock has increased by 10.5% and is now trading at $14.90. View the best growth stocks for 2024 here. When is Orthofix Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our OFIX earnings forecast. How were Orthofix Medical's earnings last quarter? Orthofix Medical Inc. (NASDAQ:OFIX) announced its quarterly earnings data on Tuesday, March, 5th. The medical device company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.01. The medical device company had revenue of $200.42 million for the quarter. Orthofix Medical had a negative net margin of 20.28% and a negative trailing twelve-month return on equity of 10.63%. What ETFs hold Orthofix Medical's stock? ETFs with the largest weight of Orthofix Medical (NASDAQ:OFIX) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE) and Invesco Nasdaq Future Gen 200 ETF (QQQS).iShares U.S. Medical Devices ETF (IHI). What guidance has Orthofix Medical issued on next quarter's earnings? Orthofix Medical issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $790.0 million-$795.0 million, compared to the consensus revenue estimate of $790.8 million. What is Brad Mason's approval rating as Orthofix Medical's CEO? 32 employees have rated Orthofix Medical Chief Executive Officer Brad Mason on Glassdoor.com. Brad Mason has an approval rating of 73% among the company's employees. What other stocks do shareholders of Orthofix Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Orthofix Medical investors own include AbbVie (ABBV), Enterprise Products Partners (EPD), Edwards Lifesciences (EW), Gilead Sciences (GILD), Biogen (BIIB), Pfizer (PFE), Exxon Mobil (XOM), Advanced Micro Devices (AMD), bluebird bio (BLUE) and Esperion Therapeutics (ESPR). Who are Orthofix Medical's major shareholders? Orthofix Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Russell Investments Group Ltd. (0.59%), Mutual of America Capital Management LLC (0.47%), Swiss National Bank (0.17%), GSA Capital Partners LLP (0.17%), Sei Investments Co. (0.10%) and BNP Paribas Financial Markets (0.09%). Insiders that own company stock include Catherine M Burzik, James F Hinrichs, Jon Carl Serbousek, Kevin J Kenny, Kimberley A Elting, Michael E Paolucci, Rice Doug and Shweta Maniar. View institutional ownership trends. How do I buy shares of Orthofix Medical? Shares of OFIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OFIX) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityWatch this FREE trading tutorial while it’s still availableInvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orthofix Medical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.